Video

Dr. Koyfman on Informing Patients of Reirradiation for Head and Neck Cancer

Author(s):

Shlomo Koyfman, MD

In Partnership With:

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses informing patients of reirradiation as a treatment for head and neck cancer.

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses informing patients of reirradiation as a treatment for head and neck cancer.

Researchers at 8 institutions evaluated intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) to determine outcomes in the reirradiation setting for recurrent head and neck cancer.

With this study, there is now more information to better equip patients to make decisions about their treatment options, explains Koyfman. In addition to elaborating on what the modern outcomes are, being able to provide those prognostic subgroups is going to change the way physicians discuss reirradiation with their patients.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
Aaron Gerds, MD
December 16th 2024

Expanding JAK Inhibitor Arsenal Provides Additional Options Beyond Ruxolitinib in Myelofibrosis

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Glenn J. Hanna, MD, director of the Center for Cancer Therapeutic Innovation (Early Drug Development Program), director of Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute; and an associate professor of medicine Harvard Medical School
December 5th 2024

PYX-201 Generates Responses and Contributes to Growing ADC Use in Solid Tumors

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

Suneel Kamath, MD
November 30th 2024

Targeted Therapies Remain Central to Ongoing Research in Pancreatic Cancer